Showing results (1-10 of 34) with videos related to
Sort By:
Pageof 4
Current Medicinal Chemistry|January 11, 2012
Pharmacological strategies to overcome HER2 cross-talk and Trastuzumab resistanceR NahtaThe Surgical Clinics of North America|November 26, 1999
Adjuvant systemic therapy for primary breast cancerF J Esteva, G N HortobagyiHematology/Oncology Clinics of North America|June 11, 1999
Locally advanced breast cancerF J Esteva, G N HortobagyiBreast (Edinburgh, Scotland)|October 19, 2005
Comparative assessment of lipid effects of endocrine therapy for breast cancer: implications for cardiovascular disease prevention in postmenopausal womenF J Esteva, G N HortobagyiAnnals of Oncology : Official Journal of the European Society for Medical Oncology|September 7, 2007
Expression patterns and predictive value of phosphorylated AKT in early-stage breast cancerF Andre, R Nahta, R Conforti, et al.Seminars in Oncology|March 10, 2001
Trastuzumab in combination with chemotherapy for the treatment of metastatic breast cancerM Fornier, F J Esteva, A D SeidmanBritish Journal of Cancer|July 16, 2014
HER2-positive advanced breast cancer: optimizing patient outcomes and opportunities for drug developmentJ C Singh, K Jhaveri, F J EstevaCurrent Pharmacogenomics and Personalized Medicine|March 20, 2010
Personalizing HER2-targeted therapy in metastatic breast cancer beyond HER2 status: what we have learned from clinical specimensR Nahta, S Shabaya, T Ozbay, et al.Breast Disease|February 3, 2005
Expression of erbB receptors and their ligands in breast cancer: implications to biological behavior and therapeutic responseS S Bacus, A V Gudkov, F J Esteva, et al.Pageof 4